デフォルト表紙
市場調査レポート
商品コード
1435271

抗うつ薬の世界市場レポート 2024

Antidepressants Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
抗うつ薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

抗うつ薬の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には3.5%の年間複合成長率(CAGR)で198億8,000万米ドルに成長すると予想されます。今後の成長予測は、メンタルヘルスに対する意識と擁護の高まり、ストレスやライフスタイルの変化による世界の影響、メンタルヘルスサービスの統合、精神医学における進行中の研究開発、遠隔医療と医療の利用に関連している可能性があります。遠隔メンタルヘルスサービス。予測期間中に予想される注目すべき動向には、規制の調整、市場競争の激化、ジェネリック市場の拡大、副作用プロファイルへの注目の高まり、新市場の出現などが含まれます。

精神的健康障害の世界の急増は、抗うつ薬産業の拡大に寄与する極めて重要な要因であり、かなりの数の人がうつ病、不安障害、さまざまな精神疾患などの症状に対処するためにこれらの薬に依存しています。抗うつ薬は、OCD、小児夜尿症、大うつ病性障害、重度の不安障害、双極性障害、心的外傷後ストレス障害(PTSD)、社会不安障害など、さまざまな障害の治療に応用されています。世界のうつ病の有病率は2%から6%の範囲であり、高齢者は他の年齢層と比べてより高いリスクに直面しています。世界保健機関(WHO)によると、2023年には世界中で約2億8,000万人がうつ病に苦しんでおり、抗うつ薬市場の原動力としてメンタルヘルス障害の増加が浮き彫りになっています。

精神疾患の発生率の増加により、将来、抗うつ薬市場の需要が促進されると予想されます。思考、感情、行動、信念の混乱を特徴とする精神疾患は、社会的、職業的、または家族の活動に課題をもたらします。 抗うつ薬は、うつ病、不安、気分障害などのさまざまな精神的健康状態に対処するために設計された医薬品のカテゴリーで、気分や感情の調節に関与する脳内の特定の化学物質のレベルを上昇させることによって機能します。 2022年6月に米国に本拠を置く政府機関が発表した報告書によると、2019年には世界で9億7,000万人が精神障害を患っていました。さらに全米精神病同盟は、米国成人の21%(5,290万人に相当)が精神疾患に直面していると報告しました。 2020年には、抗うつ薬市場の推進において精神疾患の増加が果たす役割を強調しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018~2023年
  • 市場規模と成長予測、2023~2028年、2033年

第6章 市場セグメンテーション

  • 世界の抗うつ薬市場、製品別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 選択的セロトニン再取り込み阻害剤(SSRI)
  • セロトニン・ノルアドレナリン再取り込み阻害剤(SNRI)
  • 三環系抗うつ薬(TCA)
  • モノアミンオキシダーゼ阻害剤(MAOI)
  • 世界の抗うつ薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • モノアミンオキシダーゼ阻害剤
  • セロトニンアンタゴニストと再取り込み阻害剤
  • セロトニン-ノルアドレナリン再取り込み阻害剤
  • 選択的セロトニン再取り込み阻害剤
  • 三環系抗うつ薬
  • 世界の抗うつ薬市場、うつ病別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 大うつ病性障害
  • 強迫性障害
  • 全般性不安障害
  • パニック障害

第7章 地域および国の分析

  • 世界の抗うつ薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の抗うつ薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 抗うつ薬市場の競合情勢
  • 抗うつ薬市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co. Inc.
    • AbbVie Inc.

第31章 その他の大手および革新的な企業

  • Novartis AG
  • Sanofi SA
  • Bristol Myers Squibb Company
  • Fresenius Kabi AG
  • Abbott Laboratories
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Co. Ltd.
  • Eli Lilly and Company
  • Boehringer Ingelheim GmbH
  • H. Lundbeck AS
  • Teva Pharmaceutical Industries Ltd.
  • Akeda Pharmaceutical Co.
  • Otsuka Pharmaceutical Co.
  • Mylan NV

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14985

Antidepressants are medications designed to alleviate depressive symptoms, and they can also be effective in addressing seasonal affective disorder (SAD), various anxiety disorders, and social anxiety disorder. However, it's important to note that unpleasant side effects may accompany the use of antidepressants. Initially, individuals may experience common signs and symptoms such as nausea, weight gain, or disruptions in sleep patterns.

The primary categories of antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). SSRIs, a widely used medication type, are employed not only for treating depression but also for addressing certain other mental health conditions. The diverse range of drug classes encompasses monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants, all of which find application in treating major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder.

The antidepressants market research report is one of a series of new reports from The Business Research Company that provides antidepressants market statistics, including antidepressants industry global market size, regional shares, competitors with an antidepressants market share, detailed antidepressants market segments, market trends, and opportunities, and any further data you may need to thrive in the antidepressants industry. This antidepressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antidepressants market size has grown steadily in recent years. It will grow from $16.6 billion in 2023 to $17.32 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The historical period's growth can be ascribed to a rise in the prevalence of mental health disorders, heightened awareness coupled with reduced stigma, advancements in diagnostic methods, an expansion of available treatment options, and government initiatives and policies focused on mental health.

The antidepressants market size is expected to see steady growth in the next few years. It will grow to $19.88 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The forecasted growth in the upcoming period can be linked to an increase in awareness and advocacy for mental health, the global influence of stress and lifestyle changes, the integration of mental health services, ongoing research and development in psychiatry, and the utilization of telemedicine and remote mental health services. Noteworthy trends anticipated in the forecast period encompass regulatory adjustments, intensified market competition, the expansion of the generic market, a heightened focus on side effect profiles, and the emergence of new markets.

The global surge in mental health disorders is a pivotal factor contributing to the expansion of the antidepressant drug industry, with a considerable number of individuals relying on these medications to address conditions such as depression, anxiety disorders, and various mental illnesses. Antidepressant drugs find application in treating a spectrum of disorders, including OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. The prevalence of depression globally ranges from 2% to 6%, with the elderly facing a higher risk compared to other age groups. According to the World Health Organization (WHO), approximately 280 million people worldwide suffered from depression in 2023, highlighting the escalating cases of mental health disorders as a driving force for the antidepressant market.

The escalating incidence of mental illnesses is anticipated to foster the demand for the antidepressants market in the future. Mental illnesses, characterized by disruptions in thinking, feeling, behavior, or beliefs, pose challenges in social, occupational, or familial activities. Antidepressants, a category of medications designed to address various mental health conditions, including depression, anxiety, and mood disorders, function by elevating the levels of specific chemicals in the brain responsible for mood and emotion regulation. A report from a US-based government agency in June 2022 indicated that 970 million individuals globally had a mental disorder in 2019. Furthermore, the National Alliance on Mental Illness reported that 21% of US adults, equivalent to 52.9 million people, faced mental illness in 2020, underscoring the role of increasing mental illnesses in propelling the antidepressants market.

The growth of the antidepressant market faces hindrances due to the side effects associated with antidepressant drugs. Medications such as Lexapro and Celexa, used to treat depression and anxiety, may lead to common side effects such as nausea, insomnia, sweating, dry mouth, and drowsiness. More severe side effects, including excessive bleeding, seizures, and vision problems, pose additional risks. These side effects are anticipated to curtail the expansion of the antidepressant market.

A noteworthy trend in the antidepressant market is the treatment of resistant depression, with ketamine emerging as a novel therapeutic approach. Ketamine, initially used for anesthesia during surgery, stimulates glutamate development, prompting the brain to form new neural connections. This enhances the brain's adaptability and capacity to develop new pathways, aiding individuals in fostering more positive thoughts and behaviors. The Food and Drug Administration (FDA) approved esketamine, a new ketamine depression drug, in a nasal spray form for patients who have unsuccessfully tried two antidepressants before.

Major companies in the antidepressant market are strategically focusing on introducing new drugs to maximize revenue. For example, Biogen Inc and Sage Therapeutics, Inc. launched ZURZUVAE (zuranolone) in August 2023, an oral treatment for postpartum depression (PPD), addressing the underdiagnosed and undertreated condition. ZURZUVAE (zuranolone) is the first FDA-approved medication specifically designed for PPD.

In October 2021, ShineCo., Inc. announced its entry into a framework agreement to acquire a majority stake in Beijing Wonner Biotech Co., Ltd. for $30 million. This acquisition aims to collaborate on the development of SNG, a rapid-acting natural innovative medicine for antidepressant purposes. Beijing Winner is a Chinese biotechnology company specializing in the research and development of natural medicines and related products.

Major companies operating in the antidepressants market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Fresenius Kabi AG, Abbott Laboratories, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Boehringer Ingelheim GmbH, H. Lundbeck AS, Teva Pharmaceutical Industries Ltd., Akeda Pharmaceutical Co., Otsuka Pharmaceutical Co., Mylan N.V, Sun Pharmaceuticals Pvt. Ltd., Servier Laboratories, Sumitomo Dainippon Pharma Co., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Allergan PLC, Alkermes PLC, Egis Pharmaceuticals PLC, Forest Laboratories Inc.

North America was the largest region in the antidepressants market in 2023. Middle East is expected to be the largest growing region in the global antidepressants market during the forecast period. The regions covered in the antidepressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antidepressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The antidepressants market consists of sales of duloxetine, desvenlafaxine, vilazodone, citalopram, and sertraline. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antidepressants Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antidepressants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antidepressants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antidepressants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product: Selective Serotonin Reuptake Inhibitor (SSRI); Serotonin-norepinephrine Reuptake Inhibitor (SNRI); Tricyclic Antidepressant (TCA); Monoamine Oxidase Inhibitor (MAOI)
  • 2) By Drug Class: Monoamine Oxidase Inhibitors; Serotonin Antagonist And Reuptake Inhibitors; Serotonin-Norepinephrine Reuptake Inhibitors; Selective Serotonin Reuptake Inhibitors; Tricyclic Antidepressants
  • 3) By Depressive Disorder: Major Depressive Disorder; Obsessive-Compulsive Disorder; Generalized Anxiety Disorder; Panic Disorder
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antidepressants Market Characteristics

3. Antidepressants Market Trends And Strategies

4. Antidepressants Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Antidepressants Market Size and Growth

  • 5.1. Global Antidepressants Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Antidepressants Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Antidepressants Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Antidepressants Market Segmentation

  • 6.1. Global Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Selective Serotonin Reuptake Inhibitor (SSRI)
  • Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
  • Tricyclic Antidepressant (TCA)
  • Monoamine Oxidase Inhibitor (MAOI)
  • 6.2. Global Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoamine Oxidase Inhibitors
  • Serotonin Antagonist And Reuptake Inhibitors
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Selective Serotonin Reuptake Inhibitors
  • Tricyclic Antidepressants
  • 6.3. Global Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder

7. Antidepressants Market Regional And Country Analysis

  • 7.1. Global Antidepressants Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Antidepressants Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Antidepressants Market

  • 8.1. Asia-Pacific Antidepressants Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Antidepressants Market

  • 9.1. China Antidepressants Market Overview
  • 9.2. China Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Antidepressants Market

  • 10.1. India Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Antidepressants Market

  • 11.1. Japan Antidepressants Market Overview
  • 11.2. Japan Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Antidepressants Market

  • 12.1. Australia Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Antidepressants Market

  • 13.1. Indonesia Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Antidepressants Market

  • 14.1. South Korea Antidepressants Market Overview
  • 14.2. South Korea Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Antidepressants Market

  • 15.1. Western Europe Antidepressants Market Overview
  • 15.2. Western Europe Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Antidepressants Market

  • 16.1. UK Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Antidepressants Market

  • 17.1. Germany Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Antidepressants Market

  • 18.1. France Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Antidepressants Market

  • 19.1. Italy Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Antidepressants Market

  • 20.1. Spain Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Antidepressants Market

  • 21.1. Eastern Europe Antidepressants Market Overview
  • 21.2. Eastern Europe Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Antidepressants Market

  • 22.1. Russia Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Antidepressants Market

  • 23.1. North America Antidepressants Market Overview
  • 23.2. North America Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Antidepressants Market

  • 24.1. USA Antidepressants Market Overview
  • 24.2. USA Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Antidepressants Market

  • 25.1. Canada Antidepressants Market Overview
  • 25.2. Canada Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Antidepressants Market

  • 26.1. South America Antidepressants Market Overview
  • 26.2. South America Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Antidepressants Market

  • 27.1. Brazil Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Antidepressants Market

  • 28.1. Middle East Antidepressants Market Overview
  • 28.2. Middle East Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Antidepressants Market

  • 29.1. Africa Antidepressants Market Overview
  • 29.2. Africa Antidepressants Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Antidepressants Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Antidepressants Market, Segmentation By Depressive Disorder, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Antidepressants Market Competitive Landscape And Company Profiles

  • 30.1. Antidepressants Market Competitive Landscape
  • 30.2. Antidepressants Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AbbVie Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Antidepressants Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Sanofi S.A.
  • 31.3. Bristol Myers Squibb Company
  • 31.4. Fresenius Kabi AG
  • 31.5. Abbott Laboratories
  • 31.6. AstraZeneca plc
  • 31.7. GlaxoSmithKline plc
  • 31.8. Takeda Pharmaceutical Co. Ltd.
  • 31.9. Eli Lilly and Company
  • 31.10. Boehringer Ingelheim GmbH
  • 31.11. H. Lundbeck AS
  • 31.12. Teva Pharmaceutical Industries Ltd.
  • 31.13. Akeda Pharmaceutical Co.
  • 31.14. Otsuka Pharmaceutical Co.
  • 31.15. Mylan N.V

32. Global Antidepressants Market Competitive Benchmarking

33. Global Antidepressants Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Antidepressants Market

35. Antidepressants Market Future Outlook and Potential Analysis

  • 35.1 Antidepressants Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Antidepressants Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Antidepressants Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer